29/10/2026
🎗️ A Major Step Towards More Affordable Cancer Care in India
Cancer medicine prices: Significant reductions reported by NPPA
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Government of India, has published a revised Maximum Retail Price (MRP) list for non-scheduled anti-cancer medicines. The revised prices are stated to take effect from 9 November 2026.
This initiative aims to regulate excessive trade margins and improve the affordability of cancer treatment for patients and their families.
🔍 Key highlights
📌 30% trade-margin cap for 137 identified non-scheduled anti-cancer drug ingredients.
📌 543 brands and packs reportedly included in the revised price list.
📌 397 products (73%) reportedly have reduced MRPs.
📌 217 products reportedly have price reductions exceeding 50%.
📌 Price reductions of up to 90% have been reported for certain products.
💊 Examples of reported price reductions
MedicineEarlier MRPRevised MRPPalbociclib₹40,421₹2,720Anastrozole₹695.76₹73Azacitidine₹6,337₹1,495.04Bevacizumab₹21,767.70₹5,930.13Denosumab₹22,031.25₹5,941Enzalutamide₹6,578.20₹2,232Dasatinib₹2,812.50₹1,085.93
These are examples for specific brands, strengths and pack sizes. Price reductions vary across products containing the same molecule.
🏥 What does this mean for cancer care?
✅ Potentially lower medicine expenditure for patients using affected products.
✅ An opportunity for hospitals and pharmacies to review procurement prices and patient billing.
✅ Greater importance of checking the exact brand, formulation, strength and pack size before estimating treatment costs.
⚠️ An important clarification: A reduction in MRP does not necessarily translate into an equivalent reduction in the total cost of cancer treatment. Some patented medicines remain unchanged, and actual savings depend on the product and procurement arrangement.
📊 Data transparency matters
The uploaded 38-page price-list PDF contains 643 numbered entries, whereas the reported headline refers to 543 brands and packs. This discrepancy should be reconciled against the official NPPA records before the figures are used for formal reporting.
🎯 O